Quick Answer
Enveric Biosciences, Inc. reported Diluted EPS of $36.24 per share (loss) for fiscal year 2025.
Enveric Biosciences, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$36.24 | +84.1% |
| 2024 | -$228.48 | -88.4% |
| 2023 | -$121.29 | -833.0% |
| 2022 | -$13.00 | -359.4% |
| 2019 | -$2.83 | +86.2% |
| 2018 | -$20.47 | -2629.3% |
| 2017 | -$0.75 | -257.1% |
| 2016 | -$0.21 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$10.81 | +74.9% | -1014.4% |
| June 30, 2025 | -$0.97 | +73.9% | +20.5% |
| March 31, 2025 | -$1.22 | +86.8% | +97.2% |
| September 30, 2024 | -$43.10 | -3215.4% | -1058.6% |
| June 30, 2024 | -$3.72 | -22.4% | +59.6% |
| March 31, 2024 | -$9.21 | -298.7% | -608.5% |
| September 30, 2023 | -$1.30 | +11.0% | +57.2% |
| June 30, 2023 | -$3.04 | -11.4% | -31.6% |
- Enveric Biosciences, Inc. showed an increase of +84.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2016–2025 period, Enveric Biosciences, Inc.’s diluted eps has declined by 17157.1% (from $0.21 per share (loss) to $36.24 per share (loss)).
- The most recent figure is from Enveric Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: